Cargando…
When Prostate Cancer Circulates in the Bloodstream
Management of patients with prostate cancer is currently based on imperfect clinical, biological, radiological and pathological evaluation. Prostate cancer aggressiveness, including metastatic potential, remains difficult to accurately estimate. In an attempt to better adapt therapeutics to an indiv...
Autor principal: | Vlaeminck-Guillem, Virginie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728468/ https://www.ncbi.nlm.nih.gov/pubmed/26854164 http://dx.doi.org/10.3390/diagnostics5040428 |
Ejemplares similares
-
Extracellular Vesicles in Prostate Cancer Carcinogenesis, Diagnosis, and Management
por: Vlaeminck-Guillem, Virginie
Publicado: (2018) -
Clinical utility of the nuclear-localized AR-V7 biomarker for treatment choice in metastatic castration-resistant prostate cancer
por: Vlaeminck-Guillem, Virginie
Publicado: (2020) -
Src: Marker or Actor in Prostate Cancer Aggressiveness
por: Vlaeminck-Guillem, Virginie, et al.
Publicado: (2014) -
Her2 Expression in Circulating Tumor Cells Is Associated with Poor Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Maillet, Denis, et al.
Publicado: (2021) -
MEN1 silencing aggravates tumorigenic potential of AR-independent prostate cancer cells through nuclear translocation and activation of JunD and β-catenin
por: Luo, Yakun, et al.
Publicado: (2021)